Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro.

Yufeng D, Guocheng Z, Dongliang X, Rong F, Yuhong C, Ruying L, Jingshi Z, Xuhong Z.

Med Oncol. 2009;26(1):78-85. doi: 10.1007/s12032-008-9093-8.

PMID:
18810669
2.

Dendritic cell-tumor fusion vaccines for renal cell carcinoma.

Avigan D.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6347S-52S. Review.

3.

Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies.

Schott M, Seissler J.

Trends Endocrinol Metab. 2003 May-Jun;14(4):156-62. Review.

PMID:
12714275
4.

Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas.

Cho DY, Lin SZ, Yang WK, Hsu DM, Lee HC, Lee WY, Liu SP.

Cell Transplant. 2009;18(9):977-83. doi: 10.3727/096368909X12483162196962. Review.

PMID:
19523342
5.

The 'kiss of death' by dendritic cells to cancer cells.

Chan CW, Housseau F.

Cell Death Differ. 2008 Jan;15(1):58-69. Review.

6.

Dendritic cells and their role in cancer immunotherapy.

Jalili A.

Iran J Immunol. 2007 Sep;4(3):127-44. Review.

PMID:
17767012
7.
8.

[Development of effective antigen delivery carrier to dendritic cells via Fc receptor in cancer immunotherapy].

Suzuki R, Utoguchi N, Kawamura K, Kadowaki N, Okada N, Takizawa T, Uchiyama T, Maruyama K.

Yakugaku Zasshi. 2007 Feb;127(2):301-6. Review. Japanese.

9.

Recent clinical development of dendritic cell-based immunotherapy for prostate cancer.

Rini B.

Expert Opin Biol Ther. 2004 Nov;4(11):1729-34. Review.

PMID:
15500401
10.

Dendritic cell-based immunotherapy in thyroid malignancies.

Schott M, Scherbaum WA, Seissler J.

Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep;4(3):245-51. Review.

PMID:
15379726
11.

Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.

Shu S, Zheng R, Lee WT, Cohen PA.

Crit Rev Immunol. 2007;27(5):463-83. Review.

PMID:
18197808
12.

Receptor-mediated delivery of antigens to dendritic cells: anticancer applications.

Proudfoot O, Apostolopoulos V, Pietersz GA.

Mol Pharm. 2007 Jan-Feb;4(1):58-72. Review.

PMID:
17228857
13.

Dendritic cell-based immunotherapy.

Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):377-413. Review.

PMID:
17169781
14.

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.

Jinushi M, Hodi FS, Dranoff G.

Immunol Rev. 2008 Apr;222:287-98. doi: 10.1111/j.1600-065X.2008.00618.x. Review.

PMID:
18364009
15.

The use of dendritic cells in cancer immunotherapy.

Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P.

Crit Rev Oncol Hematol. 2008 Mar;65(3):191-9. Review.

PMID:
18055210
16.

Immunotherapy of cancer using dendritic cells.

Morse MA, Lyerly HK.

Cytokines Cell Mol Ther. 1998 Mar;4(1):35-44. Review.

PMID:
9557215
17.

The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment.

Wertel I, Barczynski B, Kotarski J.

Front Biosci. 2008 Jan 1;13:2177-90. Review.

PMID:
17981701
18.

Vaccination therapy with tumor-dendritic cell hybrids: a promising therapeutic approach?

Haenssle HA.

Curr Opin Investig Drugs. 2005 Dec;6(12):1240-5. Review.

PMID:
16370389
19.
20.

[Immunotherapy based on dendritic cells: from experimentation to clinical development].

Goldman M.

Pathol Biol (Paris). 2003 Mar;51(2):74-5. Review. French.

PMID:
12801806
Items per page

Supplemental Content

Support Center